Search Results - tetsuya+takagawa

1 Results

Sort By:

LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders

Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing...

Published: 10/28/2024 | Inventor(s): Tetsuya Takagawa, Atsushi Kitani, Warren Strober

Keywords(s): COLITIS, Crohn's, Disease, IB3XXX, inhibitor, LRRK2, TREAT, Ulcerative, VPXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Endocrinology, TherapeuticArea > Infectious Disease, TherapeuticArea > Dental, TherapeuticArea > Ophthalmology, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Cardiology